Aerie Pharmaceuticals Inc (NASDAQ:AERI) is in the spotlight on Friday as the US Food and Drugs Administration is set to judge an application for its new eye drug.

Trading in the stock is on hold this morning as the FDA’s dermatologic and opthalmic drugs advisory committee will meet to review Aerie’s Rhopressa eye drop.

Rhopressa is intended to be a once daily application designed to reduce pressure on eyes resulting from glaucoma.